retatrutide phase Retatrutide: FDA approval time, trial results & weight loss New retatrutide Phase 3 data

Retrieved January 5, 2023, from Funding Open access funding provided by SCELC, Statewide California Electronic Library Consortium

All orders ship same-day from Canada with full chain of custody documentation

According to research by University College London (UCL),1.6 million UK adults used weight-loss jabs in 2025, with most buying through private prescriptions

Weight Loss Distribution The results weren't just impressive on averagethey were consistent across the patient population: Weight Loss Thresholds Achieved (12mg dose): 5% weight loss: 94.6% of participants 10% weight loss: 91.3% of participants 15% weight loss: 83.2% of participants 20% weight loss: 73.4% of participants 25% weight loss: 58.6% of participants For comparison, FDA approval for obesity medications typically requires that at least 35% of patients achieve 5% weight loss